1-6 of 6
Dezheng Huo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers

Rodrigo Santa Cruz Guindalini, Yonglan Zheng, Hiroyuki Abe, Kristen Whitaker, Toshio F. Yoshimatsu, Tom Walsh, David Schacht, Kirti Kulkarni, Deepa Sheth, Marion S. Verp, Angela R. Bradbury, Jane Churpek, Elias Obeid, Jeffrey Mueller, Galina Khramtsova, Fang Liu, Akila Raoul, Hongyuan Cao, Iris L. Romero, Susan Hong, Robert Livingston, Nora Jaskowiak, Xiaoming Wang, Marcio Debiasi, Colin C. Pritchard, Mary-Claire King, Gregory Karczmar, Gillian M. Newstead, Dezheng Huo, Olufunmilayo I. Olopade
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1786–1794.
https://doi.org/10.1158/1078-0432.CCR-18-0200
Published: 15 March 2019
View article titled, Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in <em>BRCA1</em> Mutation Carriers
Open the PDF for Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in <em>BRCA1</em> Mutation Carriers in another window
Includes: Supplementary data
Journal Articles

miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway

Ravand Samaeekia, Valery Adorno-Cruz, Jessica Bockhorn, Ya-Fang Chang, Simo Huang, Aleix Prat, Nahun Ha, Golam Kibria, Dezheng Huo, Hui Zheng, Rachel Dalton, Yuhao Wang, Grigoriy Y. Moskalenko, Huiping Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 1091–1103.
https://doi.org/10.1158/1078-0432.CCR-16-0943
Published: 14 February 2017
View article titled, miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway
Open the PDF for miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway in another window
Includes: Supplementary data
Journal Articles

Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution

Brooke E. Sylvester, Dezheng Huo, Andrey Khramtsov, Jing Zhang, Rana V. Smalling, Sope Olugbile, Blase N. Polite, Olufunmilayo I. Olopade
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 350–359.
https://doi.org/10.1158/1078-0432.CCR-11-1397
Published: 16 January 2012
View article titled, Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Open the PDF for Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution in another window
Includes: Supplementary data
Journal Articles

Advances in Breast Cancer: Pathways to Personalized Medicine

Olufunmilayo I. Olopade, Tatyana A. Grushko, Rita Nanda, Dezheng Huo
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 7988–7999.
https://doi.org/10.1158/1078-0432.CCR-08-1211
Published: 15 December 2008
View article titled, Advances in Breast Cancer: Pathways to Personalized Medicine
Open the PDF for Advances in Breast Cancer: Pathways to Personalized Medicine in another window
Journal Articles

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Olatoyosi M. Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Stephen J. Brandt, Margaret Green, Jingping Xie, Yanming Zhang, David H. Vesole, Patrick Stiff, John Wright, Richard A. Larson, Wendy Stock
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7095–7101.
https://doi.org/10.1158/1078-0432.CCR-08-1007
Published: 03 November 2008
View article titled, Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia
Open the PDF for Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia in another window
Journal Articles

Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ezra E.W. Cohen, Madeleine A. Kane, Marcy A. List, Bruce E. Brockstein, Bhoomi Mehrotra, Dezheng Huo, Ann M. Mauer, Carolyn Pierce, Allison Dekker, Everett E. Vokes
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8418–8424.
https://doi.org/10.1158/1078-0432.CCR-05-1247
Published: 01 December 2005
View article titled, Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in another window